Expert consensus on the clinical use of cladribine tablets for treating relapsing multiple sclerosis in the asia-pacific region
Authors:
- 4 December 2025
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 105, 106897
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
- Merck Healthcare KGaA (10.13039/100,009,945)
This publication has 41 references indexed in Scilit:
- Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis CentersNeurology and Therapy, 2022
- Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s ReviewNeurology and Therapy, 2022
- A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in ChilePharmacoEconomics - Open, 2021
- Long-term safety data from the cladribine tablets clinical development program in multiple sclerosisMultiple Sclerosis and Related Disorders, 2020
- Long Term Effectiveness of Cladribine in Patients Enrolled in the CLARITY Trial: Real World Experience from the Lebanese CohortMultiple Sclerosis and Related Disorders, 2020
- Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2019
- Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysisMultiple Sclerosis and Related Disorders, 2019
- Cladribine Tablets: A Review in Relapsing MSCNS Drugs, 2018
- Cladribine to Treat Relapsing Forms of Multiple SclerosisNeurotherapeutics, 2017
- Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple SclerosisArchives of Neurology, 2006